Evidence map›Paper›PMID 30429708›Full record

ArticlePostepy dermatologii i alergologii2018

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.

Krzysztof Pałgan, Magdalena Żbikowska-Götz, Kinga Lis, Elżbieta Chrzaniecka, Zbigniew Bartuzi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Postepy dermatologii i alergologii, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Krzysztof PałganDepartment of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Magdalena Żbikowska-GötzDepartment of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Kinga LisDepartment of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Elżbieta ChrzanieckaDepartment of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Zbigniew BartuziDepartment of Allergy, Clinical Immunology and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAsthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

aimTo analyse forced expiratory volume in 1 s (FEV MATERIAL AND

methodsSix patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

resultsTreatment with omalizumab increased in all subjects FEV

conclusionsThese results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.

Indexed as

asthmaforced expiratory volume in 1 somalizumabspirometry

Identifiers

PMID30429708
PMCPMC6232554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.